Get the Daily Brief
Latest Biotech News
Rice wins ARPA‑H grant to bioprint kidney tissues—$24.8M boost
Rice University secured up to $24.8 million from ARPA‑H to develop bioprinted kidney tissues as part of a multi‑year effort to address the organ donor shortfall. The award funds a consortium led...
Researchers decode phantom limb movements from intraneural signals
A team published in Nature Communications a method that decodes phantom limb motor commands directly from intraneural recordings, providing a new control signal source for neuroprosthetics. The...
Phage‑antibiotic combo clears resistant peritonitis in preclinical model
Researchers reported in Nature Communications that combining bacteriophages with antibiotics eradicated refractory Klebsiella pneumoniae peritonitis in a preclinical peritoneal dialysis model. The...
ADAPT‑MS trains clinical proteomic classifiers directly from discovery data
A Max Planck Institute team introduced ADAPT‑MS, an informatics framework that trains clinical classifiers on discovery proteomics data and adapts models at the individual‑sample level, aiming to...
Hims backs down: Stops selling compounded Wegovy after federal pressure
Telehealth firm Hims & Hers announced it will stop offering a compounded version of Novo Nordisk’s Wegovy after escalating legal and regulatory pressure. The company moved to halt distribution...
HHS scraps 340B rebate pilot — providers claim a win
The Department of Health and Human Services announced it will abandon the proposed 340B rebate pilot after hospitals and providers sued to block the plan. Providers argued the pilot would create...
uniQure pauses Fabry gene‑therapy doses after liver toxicities
Gene‑therapy developer uniQure paused mid‑ and high‑dose cohorts in its Fabry disease AAV trial after two patients experienced dose‑limiting liver toxicities, including grade 3 transaminase...
IPO comeback: Eikon prices $381m; four drugmakers raise nearly $1bn
Public markets showed renewed appetite for biotech this week as Eikon Therapeutics priced an upsized IPO that will generate approximately $381 million and several other drugmakers completed...
Adaptive bets on MRD: Company forecasts double‑digit growth for 2026
Adaptive Biotechnologies provided bullish 2026 guidance driven by growth in its minimal residual disease (MRD) business, projecting 22% year‑over‑year revenue growth for MRD at the midpoint and...
Intraneural recordings decode phantom limb movements — neuroprosthetics advance
Researchers published a Nature Communications study demonstrating a method to decode phantom limb motor commands directly from intraneural peripheral nerve recordings. The team showed that signals...
3D gut‑brain‑vascular platform reveals disease links
A Nature Communications team unveiled a 3D gut‑brain‑vascular tissue platform that models bidirectional interactions between enteric, vascular, and neural compartments. The system captures...
Phage plus antibiotic clears resistant Klebsiella peritonitis in model
A Nature Communications study reported that a combined bacteriophage‑antibiotic therapy successfully treated refractory peritoneal dialysis‑related peritonitis caused by multidrug‑resistant...
Pancreatic cancer: Inflammasome and epigenetic levers identified
Two studies unveiled complementary mechanisms that could reshape pancreatic ductal adenocarcinoma strategies. One team (Nature Communications) identified the inflammasome protein ASC as a...
Bispecific siRNAs silence two cancer genes at once
Researchers from Nitto Denko reported a bispecific siRNA design that simultaneously knocks down two genes—YAP1 and WWTR1 (TAZ)—in the Hippo pathway, aiming to overcome redundancy that enables...
Hims halts compounded GLP‑1 offering after US scrutiny
Telehealth firm Hims & Hers told customers it stopped offering a compounded pill modeled on Novo Nordisk’s Wegovy after regulators escalated legal pressure. Novo Nordisk and federal agencies...
Bayer unveils Phase 3 win: asundexian lowers secondary stroke risk
Bayer reported Phase 3 data showing its oral Factor XIa inhibitor asundexian reduced recurrence of secondary stroke by 26% versus control without raising bleeding rates. The trial readout...
uniQure pauses higher doses in Fabry gene therapy after liver toxicities
uniQure announced a dosing pause in its Fabry disease AAV gene therapy program after two patients at higher dose levels experienced grade‑3 liver enzyme elevations. The company halted mid‑ and...
Next‑gen GLP‑1 and multi‑hormone drugs promise larger weight losses
New investigational obesity drugs that target multiple gut hormones—examples include Cagrisema and retatrutide—are reporting weight‑loss magnitudes that exceed current GLP‑1 therapies in early...
TrumpRx rollout draws scrutiny: discounts limited, generics undercut claims
The White House launched TrumpRx, an online drug‑pricing portal offering discounted cash prices on a selected list of medicines, but early analysis shows limited benefit for many insured patients....
Biotech IPO surge: Eikon prices big debut as market appetite returns
Biotech public markets saw a notable week as multiple companies priced IPOs, led by Eikon Therapeutics’ upsized offering. Eikon sold shares to raise roughly $381 million to advance a cancer...